ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
June 04, 2021June 1 is World Hypopara Awareness Day. VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs, announced that it has obtained the investigational new drug (IND) approval from the ... -
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
January 08, 2021VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market and hoping to provide more Chinese patients quick access to the ...
Pharma Sources Insight January 2025
